8.44
+0.25(+3.05%)
Currency In USD
| Previous Close | 8.19 |
| Open | 8.23 |
| Day High | 8.45 |
| Day Low | 8.17 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.8 |
| Volume | 15,067 |
| Average Volume | 88,555 |
| Market Cap | 78.09M |
| PE | -2.91 |
| EPS | -2.9 |
| Moving Average 50 Days | 8.02 |
| Moving Average 200 Days | 8.16 |
| Change | 0.25 |
If you invested $1000 in CervoMed Inc. (CRVO) 10 years ago, it would be worth $0.06 as of December 14, 2025 at a share price of $8.44. Whereas If you bought $1000 worth of CervoMed Inc. (CRVO) shares 5 years ago, it would be worth $158.5 as of December 14, 2025 at a share price of $8.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
GlobeNewswire Inc.
Dec 04, 2025 10:00 PM GMT
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggestin
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic pr
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating the utility of neflamapimod and its effects on key